Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
IT Outsourcing

PUBLISHER: Grand View Research | PRODUCT CODE: 1493242

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1493242

Biotechnology And Pharmaceutical Services Outsourcing Market Size, Share & Trends Analysis Report By Service (Consulting, Auditing & Assessment), By End-use (Pharmaceutical Companies, Biotech Companies), By Region, And Segment Forecasts, 2024 - 2030

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Biotechnology And Pharmaceutical Services Outsourcing Market Growth & Trends:

The global biotechnology and pharmaceutical services outsourcing market size is expected to reach USD 66.95 billion by 2030, registering a CAGR of 5.67% from 2024 to 2030, according to a new report by Grand View Research, Inc.

The growing R&D investment for innovative therapeutics by pharmaceutical and biotechnology companies, which are complex and require strict timeline follow-up, is driving outsourcing trend in the industry. Moreover, high costs associated with the new drug development in the biotechnology and pharmaceutical industries lead to customer's preference for cost-effective outsourcing solutions. CROs have the required expertise and infrastructure that provide the benefit of cost, time, and efficiency. Moreover, emerging economies, such as Japan, India, and China are mostly preferred countries for outsourcing activities, owing to strong availability of experts, R&D infrastructure, and affordability.

In addition, regulatory framework for drug discovery and development is complex in several countries. Thus, increasing need for expertise in different areas of drug development is driving the demand for outsourcing services. Drug companies are not only outsourcing production of medicines but also clinical trials. Moreover, the outsourcing of manufacturing activities to developing countries such as China, India, and Latin America is growing due to expanding privatization of clinical trials. Additionally, the globalization of clinical trials has increased the demand for outsourcing services, particularly in emerging markets such as Latin America and MEA owing to large patient pool and lower costs

Regulatory approval procedures are becoming more stringent & time-consuming, and business players aim to receive product approvals at the first attempt to gain a higher market share. Pharmaceutical and biotechnology companies are required to have an in-house regulatory department or outsource their regulatory affairs functions due to stringent regulatory requirements in developed countries and changing regulations in developing countries. Establishing an in-house regulatory affairs department in offshore countries is not feasible, thus companies are adopting different outsourcing models depending upon size and priority of projects, thereby contributing to the growth of global biotechnology/pharmaceutical services outsourcing market.

Pharmaceutical and biotechnology companies are now focusing on their core competencies and outsourcing non-core functions to increase their productivity & operational efficiency. These companies commonly outsource R&D functions to emerging regions, such as Asia Pacific, and have now started outsourcing product design & development to CROs to reduce cost & increase focus on core functions. Small- or mid-sized companies, which do not have in-house capabilities, have to outsource their product design and development, auditing, and regulatory affairs to enter into new markets. Small or specialty companies are hiring CRO consultants to assist in regulatory affairs and legal representation functions in international markets.

Biotechnology And Pharmaceutical Services Outsourcing Market Report Highlights:

  • Based on services, the consulting segment dominated the market in 2023. The high segment growth is driven by increasing changes in regulations by several regulatory authorities such as U.S. FDA and EMA creating the need for regulatory compliance for pharmaceutical & biotech companies. Pharmaceutical and biotech products may face withdrawals, recalls, repacking, or relabeling if products are not compliant with the regulatory standards, thereby preferring consulting services from third party organizations to ensure compliance with evolving regulations
  • Based on end-use, the pharmaceutical companies segment held majority revenue share, accounting of over 58.44% in 2023. Growth in the segment can be attributed to factors such as increase in outsourcing of regulatory services and product design & development services by pharmaceutical companies to avoid high capital expenditure and increase profit margins
  • Asia Pacific dominated the market with a share of 42.41% in 2023. The regional growth is owing to surge in R&D investments by developed countries and numerous regulatory reforms in clinical trial assessment to align with regulatory guidelines of various countries investing in the region
Show more
Product Code: GVR-1-68038-326-3

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Details of primary research
  • 1.6. Market Formulation & Validation
  • 1.7. Region-wise Market Calculation
    • 1.7.1. Region-Wise Market: Base Estimates
    • 1.7.2. Global Market: CAGR Calculation
    • 1.7.3. Region Based Segment Share Calculation
  • 1.8. Model Details
    • 1.8.1. Commodity flow analysis (Model 1)
      • 1.8.1.1. Approach 1: Commodity flow approach
    • 1.8.2. Value Chain-Based Sizing & Forecasting (Model 2)
    • 1.8.3. QFD Model Sizing & Forecasting (Model 3)
    • 1.8.4. Bottom-up Approach (Model 4)
  • 1.9. Research Scope and Assumptions
  • 1.10. List of Secondary Sources
  • 1.11. List of Primary Sources
  • 1.12. List of Abbreviations
  • 1.13. Objectives
    • 1.13.1. Objective 1
    • 1.13.2. Objective 2
    • 1.13.3. Objective 3
    • 1.13.4. Objective 4

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Biotechnology and Pharmaceutical Services Outsourcing Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Outsourcing of R&D Activities
      • 3.2.1.2. Changing Regulatory Landscape
      • 3.2.1.3. Increasing Focus on Core Competencies by Pharmaceutical and Biotechnology Companies
      • 3.2.1.4. Growing Drug Development Costs Coupled With High Clinical Development Failure Rates
      • 3.2.1.5. Increasing Mergers and Collaborations
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Monitoring Issues and Lack of Standardization\
      • 3.2.2.2. Loss of Control
      • 3.2.2.3. Data Security Issues
  • 3.3. Technology Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. Clinical Trials Volume Analysis
  • 3.6. R&D Investment Analysis
  • 3.7. Biotechnology and Pharmaceutical Services Outsourcing Market Analysis Tools
    • 3.7.1. Porter's Five Forces Analysis
    • 3.7.2. PESTEL Analysis
  • 3.8. COVID-19 Impact Analysis

Chapter 4. Biotechnology and Pharmaceutical Services Outsourcing Market: Service Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Biotechnology and Pharmaceutical Services Outsourcing Market: Service Movement Analysis
  • 4.3. Global Biotechnology and Pharmaceutical Services Outsourcing Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
  • 4.4. Consulting
    • 4.4.1. Consulting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.2. Regulatory Consulting
      • 4.4.2.1. Regulatory Consulting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.3. Clinical Development Consulting
      • 4.4.3.1. Clinical Development Consulting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.4. Strategic Planning & Business Development Consulting
      • 4.4.4.1. Strategic Planning & Business Development Consulting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.5. Quality Management Systems Consulting
      • 4.4.5.1. Quality Management Systems Consulting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.6. Others
      • 4.4.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Regulatory Affairs
    • 4.5.1. Regulatory Affairs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.2. Legal Representation
      • 4.5.2.1. Legal Representation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.3. Regulatory Writing & Publishing
      • 4.5.3.1. Regulatory Writing & Publishing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.4. Product Registration & Clinical Trial Applications
      • 4.5.4.1. Product Registration & Clinical Trial Applications Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.5. Regulatory Submissions
      • 4.5.5.1. Regulatory Submissions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.6. Regulatory Operations
      • 4.5.6.1. Regulatory Operations Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.7. Others
      • 4.5.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Product Design & Development
    • 4.6.1. Product Design & Development Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Auditing and Assessment
    • 4.7.1. Auditing and Assessment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Product Maintenance
    • 4.8.1. Product Maintenance Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Training & Education
    • 4.9.1. Training & Education Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.10. Others
    • 4.10.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Biotechnology and Pharmaceutical Services Outsourcing Market: End-Use Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Biotechnology and Pharmaceutical Services Outsourcing Market: End-Use Movement Analysis
  • 5.3. Global Biotechnology and Pharmaceutical Services Outsourcing Market Size & Trend Analysis, by End-Use, 2018 to 2030 (USD Million)
  • 5.4. Pharmaceutical Companies
    • 5.4.1. Pharmaceutical Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Biotech Companies
    • 5.5.1. Biotech Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Biotechnology and Pharmaceutical Services Outsourcing Market: Regional Estimates & Trend Analysis, by Service, by End-Use

  • 6.1. Regional Dashboard
  • 6.2. Biotechnology and Pharmaceutical Services Outsourcing Market: Regional Movement Analysis
  • 6.3. North America
    • 6.3.1. North America Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Key Country Dynamics
      • 6.3.2.2. Competitive Scenario
      • 6.3.2.3. Regulatory Framework
      • 6.3.2.4. U.S. Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Key Country Dynamics
      • 6.3.3.2. Competitive Scenario
      • 6.3.3.3. Regulatory Framework
      • 6.3.3.4. Canada Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. Europe Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. UK
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Competitive Scenario
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. UK Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Germany
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Competitive Scenario
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Germany Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. France
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Competitive Scenario
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. France Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.5. Italy
      • 6.4.5.1. Key Country Dynamics
      • 6.4.5.2. Competitive Scenario
      • 6.4.5.3. Regulatory Framework
      • 6.4.5.4. Italy Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.6. Spain
      • 6.4.6.1. Key Country Dynamics
      • 6.4.6.2. Competitive Scenario
      • 6.4.6.3. Regulatory Framework
      • 6.4.6.4. Spain Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.7. Denmark
      • 6.4.7.1. Key Country Dynamics
      • 6.4.7.2. Competitive Scenario
      • 6.4.7.3. Regulatory Framework
      • 6.4.7.4. Denmark Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.8. Sweden
      • 6.4.8.1. Key Country Dynamics
      • 6.4.8.2. Competitive Scenario
      • 6.4.8.3. Regulatory Framework
      • 6.4.8.4. Sweden Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.9. Norway
      • 6.4.9.1. Key Country Dynamics
      • 6.4.9.2. Competitive Scenario
      • 6.4.9.3. Regulatory Framework
      • 6.4.9.4. Norway Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Asia Pacific Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. Japan
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Competitive Scenario
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Japan Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. China
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Competitive Scenario
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. China Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. India
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Competitive Scenario
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. India Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Australia
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Competitive Scenario
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Australia Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Competitive Scenario
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Thailand Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. South Korea
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Competitive Scenario
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. South Korea Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Latin America Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Brazil
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Competitive Scenario
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Brazil Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. Mexico
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Competitive Scenario
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Mexico Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. Argentina
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Competitive Scenario
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Argentina Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Middle East & Africa
    • 6.7.1. Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. South Africa
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Competitive Scenario
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. South Africa Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Saudi Arabia
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Competitive Scenario
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.4. UAE
      • 6.7.4.1. Key Country Dynamics
      • 6.7.4.2. Competitive Scenario
      • 6.7.4.3. Regulatory Framework
      • 6.7.4.4. UAE Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.5. Kuwait
      • 6.7.5.1. Key Country Dynamics
      • 6.7.5.2. Competitive Scenario
      • 6.7.5.3. Regulatory Framework
      • 6.7.5.4. Kuwait Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
    • 7.1.1. Market Leaders
    • 7.1.2. Emerging Players
  • 7.2. Company Market Share/Assessment Analysis, 2023
  • 7.3. Service Heat Map Analysis
  • 7.4. Company Profiles
    • 7.4.1. Parexel International Corporation
      • 7.4.1.1. Company Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Service Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. The Quantic Group
      • 7.4.2.1. Company Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Service Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. IQVIA
      • 7.4.3.1. Company Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Service Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. Lachman Consultant Services, Inc.
      • 7.4.4.1. Company Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Service Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. GMP Pharmaceuticals Pty Ltd.
      • 7.4.5.1. Company Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Service Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. Concept Heidelberg GmbH
      • 7.4.6.1. Company Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Service Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. LabCorp
      • 7.4.7.1. Company Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Service Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. Charles River Laboratories
      • 7.4.8.1. Company Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Service Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. ICON plc.
      • 7.4.9.1. Company Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Service Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. Syneos Health
      • 7.4.10.1. Company Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Service Benchmarking
      • 7.4.10.4. Strategic Initiatives
    • 7.4.11. Lonza
      • 7.4.11.1. Company Overview
      • 7.4.11.2. Financial Performance
      • 7.4.11.3. Service Benchmarking
      • 7.4.11.4. Strategic Initiatives
    • 7.4.12. Catalent Inc.
      • 7.4.12.1. Company Overview
      • 7.4.12.2. Financial Performance
      • 7.4.12.3. Service Benchmarking
      • 7.4.12.4. Strategic Initiatives
    • 7.4.13. Samsung Biologics
      • 7.4.13.1. Company Overview
      • 7.4.13.2. Financial Performance
      • 7.4.13.3. Service Benchmarking
      • 7.4.13.4. Strategic Initiatives
Show more
Product Code: GVR-1-68038-326-3

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 4 Global Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 5 Global Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 6 Global Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 7 Global Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 8 Global Biotechnology and Pharmaceutical Services Outsourcing by Region, 2018 - 2030 (USD Million)
  • Table 9 North America Biotechnology and Pharmaceutical Services Outsourcing by Country, 2018 - 2030 (USD Million)
  • Table 10 North America Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 11 North America Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 12 North America Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 13 North America Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 14 North America Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 15 U.S. Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 16 U.S. Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 17 U.S. Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 18 U.S. Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 19 U.S. Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 20 Canada Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 21 Canada Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 22 Canada Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 23 Canada Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 24 Canada Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 25 Europe Biotechnology and Pharmaceutical Services Outsourcing by Country, 2018 - 2030 (USD Million)
  • Table 26 Europe Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 27 Europe Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 28 Europe Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 29 Europe Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 30 Europe Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 31 Germany Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 32 Germany Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 33 Germany Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 34 Germany Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 35 Germany Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 36 U.K. Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 37 U.K. Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 38 U.K. Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 39 U.K. Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 40 U.K. Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 41 France Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 42 France Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 43 France Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 44 France Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 45 France Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 46 Italy Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 47 Italy Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 48 Italy Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 49 Italy Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 50 Italy Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 51 Spain Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 52 Spain Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 53 Spain Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 54 Spain Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 55 Spain Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 56 Denmark Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 57 Denmark Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 58 Denmark Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 59 Denmark Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 60 Denmark Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 61 Sweden Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 62 Sweden Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 63 Sweden Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 64 Sweden Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 65 Sweden Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 66 Norway Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 67 Norway Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 68 Norway Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 69 Norway Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 70 Norway Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 71 Asia Pacific Biotechnology and Pharmaceutical Services Outsourcing by Country, 2018 - 2030 (USD Million)
  • Table 72 Asia Pacific Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 73 Asia Pacific Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 74 Asia Pacific Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 75 Asia Pacific Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 76 Asia Pacific Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 77 China Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 78 China Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 79 China Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 80 China Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 81 China Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 82 Japan Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 83 Japan Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 84 Japan Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 85 Japan Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 86 Japan Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 87 India Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 88 India Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 89 India Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 90 India Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 91 India Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 92 South Korea Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 93 South Korea Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 94 South Korea Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 95 South Korea Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 96 South Korea Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 97 Australia Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 98 Australia Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 99 Australia Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 100 Australia Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 101 Australia Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 102 Thailand Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 103 Thailand Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 104 Thailand Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 105 Thailand Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 106 Thailand Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 107 Latin America Biotechnology and Pharmaceutical Services Outsourcing by Country, 2018 - 2030 (USD Million)
  • Table 108 Latin America Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 109 Latin America Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 110 Latin America Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 111 Latin America Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 112 Latin America Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 113 Brazil Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 114 Brazil Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 115 Brazil Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 116 Brazil Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 117 Brazil Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 118 Mexico Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 119 Mexico Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 120 Mexico Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 121 Mexico Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 122 Mexico Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 123 Argentina Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 124 Argentina Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 125 Argentina Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 126 Argentina Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 127 Argentina Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 128 Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing by Country, 2018 - 2030 (USD Million)
  • Table 129 Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 130 Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 131 Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 132 Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 133 Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 134 South Africa Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 135 South Africa Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 136 South Africa Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 137 South Africa Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 138 South Africa Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 139 Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 140 Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 141 Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 142 Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 143 Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 144 UAE Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 145 UAE Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 146 UAE Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 147 UAE Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 148 UAE Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 149 Kuwait Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 150 Kuwait Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 151 Kuwait Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 152 Kuwait Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 153 Kuwait Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Biotechnology and Pharmaceutical Services Outsourcing, Market Segmentation
  • Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 9 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 10 Porter's Five Forces Analysis
  • Fig. 11 Regional Marketplace: Key Takeaways
  • Fig. 12 Global Biotechnology and Pharmaceutical Services Outsourcing, for Consulting, 2018 - 2030 (USD Million)
  • Fig. 13 Global Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Consulting, 2018 - 2030 (USD Million)
  • Fig. 14 Global Biotechnology and Pharmaceutical Services Outsourcing, for Clinical Development Consulting, 2018 - 2030 (USD Million)
  • Fig. 15 Global Biotechnology and Pharmaceutical Services Outsourcing, for Strategic Planning & Business Development Consulting, 2018 - 2030 (USD Million)
  • Fig. 16 Global Biotechnology and Pharmaceutical Services Outsourcing, for Quality Management Systems Consulting, 2018 - 2030 (USD Million)
  • Fig. 17 Global Biotechnology and Pharmaceutical Services Outsourcing, for Others, 2018 - 2030 (USD Million)
  • Fig. 18 Global Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Affairs, 2018 - 2030 (USD Million)
  • Fig. 19 Global Biotechnology and Pharmaceutical Services Outsourcing, for Legal Representation, 2018 - 2030 (USD Million)
  • Fig. 20 Global Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • Fig. 21 Global Biotechnology and Pharmaceutical Services Outsourcing, for Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • Fig. 22 Global Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Submissions, 2018 - 2030 (USD Million)
  • Fig. 23 Global Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Operations, 2018 - 2030 (USD Million)
  • Fig. 24 Global Biotechnology and Pharmaceutical Services Outsourcing, for Others, 2018 - 2030 (USD Million)
  • Fig. 25 Global Biotechnology and Pharmaceutical Services Outsourcing, for Product Design & Development, 2018 - 2030 (USD Million)
  • Fig. 26 Global Biotechnology and Pharmaceutical Services Outsourcing, for Research, Strategy, & Concept Generation, 2018 - 2030 (USD Million)
  • Fig. 27 Global Biotechnology and Pharmaceutical Services Outsourcing, for Concept & Requirements Development, 2018 - 2030 (USD Million)
  • Fig. 28 Global Biotechnology and Pharmaceutical Services Outsourcing, for Detailed Design & Process Development, 2018 - 2030 (USD Million)
  • Fig. 29 Global Biotechnology and Pharmaceutical Services Outsourcing, for Design Verification & Validation , 2018 - 2030 (USD Million)
  • Fig. 30 Global Biotechnology and Pharmaceutical Services Outsourcing, for Process Validation & Manufacturing Transfer , 2018 - 2030 (USD Million)
  • Fig. 31 Global Biotechnology and Pharmaceutical Services Outsourcing, for Production & Commercial Support, 2018 - 2030 (USD Million)
  • Fig. 32 Global Biotechnology and Pharmaceutical Services Outsourcing, for Pharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 33 Global Biotechnology and Pharmaceutical Services Outsourcing, for Biotech Companies, 2018 - 2030 (USD Million)
  • Fig. 34 Regional Outlook, 2023 & 2030
  • Fig. 35 North America Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Canada Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Europe Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Germany Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 UK Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 France Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Italy Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Spain Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Denmark Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Sweden Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Norway Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Asia Pacific Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Japan Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 China Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 India Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Australia Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 South Korea Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Thailand Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Latin America Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Brazil Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Mexico Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Argentina Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Middle East and Africa Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 South Africa Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 UAE Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Kuwait Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!